Teladoc Health, Inc. ($TDOC) reported its third-quarter 2024 earnings, surpassing analyst expectations with revenues of $640.5 million, compared to estimates of $631.16 million. The company reported a net loss of $33.3 million, or $0.19 per share, which also beat estimates of a $0.28 loss per share. Despite a year-over-year revenue decline of 3%, shares rose 10% in extended trading following the announcement. Teladoc is forecasting a modest growth of 0% to 2.5% year-over-year for the fourth quarter, contrasting with street estimates predicting a decline of 4.55%. The CEO highlighted the need for strategic adjustments to address the company's post-pandemic challenges.